Silke C. Hofmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Silke C. Hofmann has a total of 214 co-authors. Here are the top co-authors by number of shared publications:
- Galina Balakirski
Zentrum für Dermatologie Allergologie und Dermatochirurgie HELIOS Universitätsklinikum Wuppertal Universität Witten/Herdecke Wuppertal Deutschland
8 shared publications - Alexander Kreuter
Klinik für Dermatologie Venerologie und Allergologie Helios St. Elisabeth Klinik Oberhausen Universität Witten/Herdecke Oberhausen Deutschland
7 shared publications Percy Lehmann
Zentrum für Dermatologie Allergologie und Dermatochirurgie Helios Universitätsklinikum Wuppertal Universität Witten/Herdecke, Wuppertal
5 shared publicationsOliver Schmalz
Department for Hematology, Oncology and Palliative Medicine, Helios University Hospital Wuppertal, University Witten/Herdecke, Wuppertal, Germany
4 shared publications- Angelo Valerio Marzano
Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
3 shared publications - Enno Schmidt
Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
3 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (11) , 1665-1668
Retronychie: Operative Therapie und postoperative Versorgung
- 10 November 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (11) , 1665-1668
Open AccessRetronychie: Operative Therapie und postoperative Versorgung
- 16 July 2026
- Published by Springer Nature in Die Dermatologie
- Vol. 77 (S3) , 106-110
53/w mit schmerzhaften Erosionen der Mundschleimhaut
- 16 July 2026
- Published by Springer Nature in Die Dermatologie
- Vol. 77 (S3) , 106-110
53/w mit schmerzhaften Erosionen der Mundschleimhaut
- Open Access
- 14 June 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Trust in skincare and topical therapies in atopic dermatitis or psoriasis: a German cross‐sectional study
Summary: Background and objectives: Trust in therapy impacts adherence and satisfaction in chronic inflammatory skin diseases, including atopic dermatitis (AD) and psoriasis (PSO). This study assessed and compared trust in skincare and topical therapies and explored influencing factors among AD and PSO patients. Patients and methods: Cross‐sectional surveys of AD or PSO patients were conducted at two dermatological university centers in Germany. Group differences were analyzed using Mann‐Whitney U and Kruskal‐Wallis tests; associations between trust (6‐point Likert scale: 1 = very high, 6 = none) and demographics, disease severity, pruritus, pain, and quality of life (QoL) using Spearman correlations. All analyses were exploratory. Results: Among 253 AD or PSO patients (median age 53.0 years, interquartile range 36.0–63.0; 43.9% female) median trust in skin care and topical therapies was moderate. AD patients reported significantly higher trust than PSO patients. In AD, trust in skin care correlated with pruritus intensity ( p < 0.001), pain intensity ( p < 0.05), and QoL ( p < 0.001); trust in topical therapy correlated with QoL ( p < 0.01). No significant correlations were observed in PSO. Conclusions: Trust levels were higher in AD than in PSO but tended to decline with increasing disease burden and poorer QoL. Enhancing patient education and shared decision‐making may help improve trust and adherence.
- 14 June 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Open AccessTrust in skincare and topical therapies in atopic dermatitis or psoriasis: a German cross‐sectional study
Summary: Background and objectives: Trust in therapy impacts adherence and satisfaction in chronic inflammatory skin diseases, including atopic dermatitis (AD) and psoriasis (PSO). This study assessed and compared trust in skincare and topical therapies and explored influencing factors among AD and PSO patients. Patients and methods: Cross‐sectional surveys of AD or PSO patients were conducted at two dermatological university centers in Germany. Group differences were analyzed using Mann‐Whitney U and Kruskal‐Wallis tests; associations between trust (6‐point Likert scale: 1 = very high, 6 = none) and demographics, disease severity, pruritus, pain, and quality of life (QoL) using Spearman correlations. All analyses were exploratory. Results: Among 253 AD or PSO patients (median age 53.0 years, interquartile range 36.0–63.0; 43.9% female) median trust in skin care and topical therapies was moderate. AD patients reported significantly higher trust than PSO patients. In AD, trust in skin care correlated with pruritus intensity ( p < 0.001), pain intensity ( p < 0.05), and QoL ( p < 0.001); trust in topical therapy correlated with QoL ( p < 0.01). No significant correlations were observed in PSO. Conclusions: Trust levels were higher in AD than in PSO but tended to decline with increasing disease burden and poorer QoL. Enhancing patient education and shared decision‐making may help improve trust and adherence.
- Open Access
- 28 April 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (4) , 100
General health versus tumor stage: determinants of survival in Merkel cell carcinoma assessed by sentinel lymph node biopsy
Purpose: Overall survival (OS) of Merkel cell carcinoma (MCC) patients is strongly influenced by health. Sentinel lymph node biopsy (SLNB) is recommended for staging. We evaluated whether SLNB is associated with OS in clinically node-negative MCC and contrasted tumor factors with patient frailty. Methods: STROBE-compliant cohort across eight centers in Germany (2004–2024). We included 271 primary stage I–II MCC; 167 underwent SLNB and 104 did not. The primary outcome was OS; disease-specific survival (DSS) and progression-free probability (PFP) were secondary. Kaplan–Meier and Cox models were used. Confounding by indication was addressed with 1:1 propensity score matching and sensitivity analyses. Results: Patients receiving SLNB were younger (median 74 vs 82 years; p < 0.001) and less comorbid (Charlson 4 vs 5). Ten-year OS was 69.5% with SLNB versus 45.2% without (log-rank p < 0.0001); unadjusted HR 0.34 (95% CI 0.20–0.59). In the matched cohort, SLNB remained associated with lower all-cause mortality (HR 0.56, 95% CI 0.34–0.93; p = 0.024). DSS did not differ (HR 1.09, 95% CI 0.55–2.13; p = 0.81). For PFP, unadjusted curves favored SLNB ( p =0.0045), but the matched analysis was not significant (HR 0.53, 95% CI 0.23–1.26). Sensitivity analyses suggested benefit: overlap weighting HR 0.49 (95% CI 0.33–0.73; p = 0.00045) and a stage-restricted match HR 0.36 (95% CI 0.13–0.99; p = 0.048). Conclusions: SLNB was associated with improved OS after adjustment, supporting its role in staging and risk stratification. The absence of DSS and matched PFP differences highlights the influence of overall health; residual confounding by indication cannot be excluded.
- 28 April 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (4) , 100
Open AccessGeneral health versus tumor stage: determinants of survival in Merkel cell carcinoma assessed by sentinel lymph node biopsy
Purpose: Overall survival (OS) of Merkel cell carcinoma (MCC) patients is strongly influenced by health. Sentinel lymph node biopsy (SLNB) is recommended for staging. We evaluated whether SLNB is associated with OS in clinically node-negative MCC and contrasted tumor factors with patient frailty. Methods: STROBE-compliant cohort across eight centers in Germany (2004–2024). We included 271 primary stage I–II MCC; 167 underwent SLNB and 104 did not. The primary outcome was OS; disease-specific survival (DSS) and progression-free probability (PFP) were secondary. Kaplan–Meier and Cox models were used. Confounding by indication was addressed with 1:1 propensity score matching and sensitivity analyses. Results: Patients receiving SLNB were younger (median 74 vs 82 years; p < 0.001) and less comorbid (Charlson 4 vs 5). Ten-year OS was 69.5% with SLNB versus 45.2% without (log-rank p < 0.0001); unadjusted HR 0.34 (95% CI 0.20–0.59). In the matched cohort, SLNB remained associated with lower all-cause mortality (HR 0.56, 95% CI 0.34–0.93; p = 0.024). DSS did not differ (HR 1.09, 95% CI 0.55–2.13; p = 0.81). For PFP, unadjusted curves favored SLNB ( p =0.0045), but the matched analysis was not significant (HR 0.53, 95% CI 0.23–1.26). Sensitivity analyses suggested benefit: overlap weighting HR 0.49 (95% CI 0.33–0.73; p = 0.00045) and a stage-restricted match HR 0.36 (95% CI 0.13–0.99; p = 0.048). Conclusions: SLNB was associated with improved OS after adjustment, supporting its role in staging and risk stratification. The absence of DSS and matched PFP differences highlights the influence of overall health; residual confounding by indication cannot be excluded.
- Open Access
- 19 March 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (11) , 1665-1668
Retronychia: Surgical treatment and postoperative care
- 19 March 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (11) , 1665-1668
Open AccessRetronychia: Surgical treatment and postoperative care
- Open Access
- 13 December 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (2) , 977-992
Treatment Preferences Among Systemic Therapy-Naïve Patients with Atopic Dermatitis or Psoriasis in Germany: A Multicentre Study
Introduction Despite the expanding range of approved systemic therapies for atopic dermatitis (AD) and psoriasis (PSO), data on patient preferences remain limited. It is largely unknown whether patients wish to initiate systemic treatment, which route of administration (oral versus subcutaneous) they prefer, or what factors drive their treatment preferences. This study evaluated the desire for systemic therapy among systemic treatment-naïve patients with AD or PSO, including disease-specific influencing factors and preferences for administration routes (subcutaneous injections vs. tablets). Methods Eligible patients with AD or PSO were recruited at two German university hospitals. Questionnaires collected demographic and clinical data, including disease severity, pruritus and pain intensity, quality of life (QoL) impairment, and desire for systemic therapy. Data analysis comprised Mann–Whitney U tests (between-group comparisons), and Spearman correlations (factors influencing therapy desire). Results From 253 recruited patients, systemic treatment-naïve patients with moderate-to-severe disease severity exclusively using topical therapies were selected (56 with AD, 63 with PSO); 77.8% of patients with PSO and 67.9% of patients with AD desired systemic therapy, mainly for superior efficacy, QoL improvement, and pruritus reduction. Administration preferences differed significantly (PSO 57.1% injections; AD 73.7% tablets; p < 0.005). The desire for systemic therapy moderately correlated with pain intensity (ρ = 0.422, p < 0.001) and QoL impairment (ρ = 0.379, p < 0.005) in AD and with male sex in PSO (ρ = 0.347, p < 0.005). Conclusions Most topically treated patients with moderate-to-severe AD or PSO desire systemic therapy, with distinct disease-specific administration preferences.
- 13 December 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (2) , 977-992
Open AccessTreatment Preferences Among Systemic Therapy-Naïve Patients with Atopic Dermatitis or Psoriasis in Germany: A Multicentre Study
Introduction Despite the expanding range of approved systemic therapies for atopic dermatitis (AD) and psoriasis (PSO), data on patient preferences remain limited. It is largely unknown whether patients wish to initiate systemic treatment, which route of administration (oral versus subcutaneous) they prefer, or what factors drive their treatment preferences. This study evaluated the desire for systemic therapy among systemic treatment-naïve patients with AD or PSO, including disease-specific influencing factors and preferences for administration routes (subcutaneous injections vs. tablets). Methods Eligible patients with AD or PSO were recruited at two German university hospitals. Questionnaires collected demographic and clinical data, including disease severity, pruritus and pain intensity, quality of life (QoL) impairment, and desire for systemic therapy. Data analysis comprised Mann–Whitney U tests (between-group comparisons), and Spearman correlations (factors influencing therapy desire). Results From 253 recruited patients, systemic treatment-naïve patients with moderate-to-severe disease severity exclusively using topical therapies were selected (56 with AD, 63 with PSO); 77.8% of patients with PSO and 67.9% of patients with AD desired systemic therapy, mainly for superior efficacy, QoL improvement, and pruritus reduction. Administration preferences differed significantly (PSO 57.1% injections; AD 73.7% tablets; p < 0.005). The desire for systemic therapy moderately correlated with pain intensity (ρ = 0.422, p < 0.001) and QoL impairment (ρ = 0.379, p < 0.005) in AD and with male sex in PSO (ρ = 0.347, p < 0.005). Conclusions Most topically treated patients with moderate-to-severe AD or PSO desire systemic therapy, with distinct disease-specific administration preferences.
- Open Access
- 24 September 2025
- Published by MDPI AG in Lymphatics
- Vol. 3 (4) , 30
Bronchiolitis Obliterans in a Young Female Patient with Paraneoplastic Pemphigus Associated with Unicentric Castleman’s Disease
Background: Castleman’s disease (CD), also known as angiofollicular lymph node hyperplasia, describes a rare group of diseases manifesting with enlarged lymph nodes and various inflammatory symptoms. The association between Castleman’s disease, paraneoplastic pemphigus and bronchiolitis obliterans has been described in the literature and is depicted thoroughly in this case. Case Presentation: We present a case of severe bronchiolitis obliterans developing in a 17-year-old female with paraneoplastic pemphigus and unicentric Castleman’s disease. Conclusion: Surgical resection of unicentric Castleman’s disease remains the treatment of choice due to its efficacy in preventing the recurrence of associated morbidity caused by bronchiolitis obliterans and paraneoplastic pemphigus.
- 24 September 2025
- Published by MDPI AG in Lymphatics
- Vol. 3 (4) , 30
Open AccessBronchiolitis Obliterans in a Young Female Patient with Paraneoplastic Pemphigus Associated with Unicentric Castleman’s Disease
Background: Castleman’s disease (CD), also known as angiofollicular lymph node hyperplasia, describes a rare group of diseases manifesting with enlarged lymph nodes and various inflammatory symptoms. The association between Castleman’s disease, paraneoplastic pemphigus and bronchiolitis obliterans has been described in the literature and is depicted thoroughly in this case. Case Presentation: We present a case of severe bronchiolitis obliterans developing in a 17-year-old female with paraneoplastic pemphigus and unicentric Castleman’s disease. Conclusion: Surgical resection of unicentric Castleman’s disease remains the treatment of choice due to its efficacy in preventing the recurrence of associated morbidity caused by bronchiolitis obliterans and paraneoplastic pemphigus.
- Open Access
- 17 September 2025
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 21 (1) , 1-5
Avapritinib reduces symptoms and mast cell burden in systemic mastocytosis
Background: Mastocytosis is driven by a clonal expansion of mast cells, commonly triggered by the KIT D816V mutation which is present in over 90% of adult patients. Individuals with indolent systemic mastocytosis (ISM) frequently experience recurrent anaphylaxis and mast cell mediator-related symptoms, leading to substantial morbidity. In rare cases, progression to more severe subtypes, such as smoldering systemic mastocytosis (SSM), can occur. Case presentation: We describe one patient with ISM and another with ISM transitioning to SSM, both treated with the selective KIT D816V inhibitor avapritinib at a daily dose of 25 mg. Following initiation of avapritinib, both patients exhibited a marked reduction in serum tryptase levels and complete remission of maculopapular cutaneous mastocytosis. Additionally, joint pain, gastrointestinal symptoms, and neurocognitive complaints decreased. Sustained clinical improvement over follow-up periods of 9 and 12 months was consistently reflected in disease-specific patient-reported outcome measures (PROMs). Conclusions: Regular clinical and laboratory monitoring, including serum tryptase and KIT D816V mutation assessment in peripheral blood, is essential in all ISM patients to detect early signs of disease progression. In refractory cases, avapritinib is a promising therapeutic option that can reduce mast cell burden, alleviate symptoms, and enhance overall quality of life.
- 17 September 2025
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 21 (1) , 1-5
Open AccessAvapritinib reduces symptoms and mast cell burden in systemic mastocytosis
Background: Mastocytosis is driven by a clonal expansion of mast cells, commonly triggered by the KIT D816V mutation which is present in over 90% of adult patients. Individuals with indolent systemic mastocytosis (ISM) frequently experience recurrent anaphylaxis and mast cell mediator-related symptoms, leading to substantial morbidity. In rare cases, progression to more severe subtypes, such as smoldering systemic mastocytosis (SSM), can occur. Case presentation: We describe one patient with ISM and another with ISM transitioning to SSM, both treated with the selective KIT D816V inhibitor avapritinib at a daily dose of 25 mg. Following initiation of avapritinib, both patients exhibited a marked reduction in serum tryptase levels and complete remission of maculopapular cutaneous mastocytosis. Additionally, joint pain, gastrointestinal symptoms, and neurocognitive complaints decreased. Sustained clinical improvement over follow-up periods of 9 and 12 months was consistently reflected in disease-specific patient-reported outcome measures (PROMs). Conclusions: Regular clinical and laboratory monitoring, including serum tryptase and KIT D816V mutation assessment in peripheral blood, is essential in all ISM patients to detect early signs of disease progression. In refractory cases, avapritinib is a promising therapeutic option that can reduce mast cell burden, alleviate symptoms, and enhance overall quality of life.
- 13 June 2025
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 122 (12) , 340
Notalgia paresthetica following an osteoporotic compression fracture
- 13 June 2025
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 122 (12) , 340
Notalgia paresthetica following an osteoporotic compression fracture
- Open Access
- 8 December 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 22 (12) , 1651-1663
Photodynamische Therapie in der Dermatologie: Bewährte und neue Indikationen
Zusammenfassung: Die photodynamische Therapie (PDT) ist international zur Behandlung von In‐situ‐Formen des keratinozytären Hautkrebses (aktinische Keratosen, Morbus Bowen, Basalzellkarzinome) zugelassen. Für diese Indikationen bestehen standardisierte Behandlungsprotokolle mit Schmalspektrum‐Lichtquellen oder (künstlichem) Tageslicht, die zu Heilung, geringer Rezidivrate der Läsionen und sehr gutem kosmetischen Ergebnis führen. Die Tageslicht‐PDT ist dabei im Hinblick auf die deutlich geringere Schmerzhaftigkeit und damit verbundene höhere Akzeptanz durch die Patienten der konventionellen PDT überlegen.Neuere Indikationen, für die noch keine Zulassung vorliegt, für die die Studienlage aber ausreichende Wirksamkeit belegt, sind entzündliche (Lichen sclerosus, Akne) und infektiöse Dermatosen (Viruswarzen, kutane Leishmaniose, atypische Mykobakteriose). Darüber hinaus wird die PDT zunehmend in der ästhetischen Dermatologie zur Hautverjüngung eingesetzt.
- 8 December 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 22 (12) , 1651-1663
Open AccessPhotodynamische Therapie in der Dermatologie: Bewährte und neue Indikationen
Zusammenfassung: Die photodynamische Therapie (PDT) ist international zur Behandlung von In‐situ‐Formen des keratinozytären Hautkrebses (aktinische Keratosen, Morbus Bowen, Basalzellkarzinome) zugelassen. Für diese Indikationen bestehen standardisierte Behandlungsprotokolle mit Schmalspektrum‐Lichtquellen oder (künstlichem) Tageslicht, die zu Heilung, geringer Rezidivrate der Läsionen und sehr gutem kosmetischen Ergebnis führen. Die Tageslicht‐PDT ist dabei im Hinblick auf die deutlich geringere Schmerzhaftigkeit und damit verbundene höhere Akzeptanz durch die Patienten der konventionellen PDT überlegen.Neuere Indikationen, für die noch keine Zulassung vorliegt, für die die Studienlage aber ausreichende Wirksamkeit belegt, sind entzündliche (Lichen sclerosus, Akne) und infektiöse Dermatosen (Viruswarzen, kutane Leishmaniose, atypische Mykobakteriose). Darüber hinaus wird die PDT zunehmend in der ästhetischen Dermatologie zur Hautverjüngung eingesetzt.